Common pathways to tumor rejection

Ena Wang, Davide Bedognetti, Sara Tomei, Francesco M. Marincola

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The control of tumor growth by the host's immunosurveillance is centered on the activation of interferon (IFN) pathways. In particular, direct study of tumors by various groups has uncovered an IFN-γ-related signature whose presence is consistently associated with better prognosis, predisposition to respond to immunotherapy, and, in its extreme manifestation, the acute phases of tumor rejection. Together, and related to the IFN-γ-associated signature, a cluster of genes are coordinately expressed that we refer to as the immunologic constant of rejection (ICR). Activation of ICR components is observed in all forms of immune-mediated, tissue-specific destruction, including autoimmunity, allograft rejection, graft-versus-host disease, and killing of affected cells during the acute phases of infection that leads to clearance of pathogens. Thus, tumor rejection is a facet of a general and conserved mechanism that favors (tumor rejection, clearance of pathogen) or encumbers (graft rejection, autoimmunity) the organism. Here, we summarize progress in the understanding of its genesis, outline the difficulties, and propose a strategy for understanding the causes of tumor rejection.

Original languageEnglish
Pages (from-to)75-79
Number of pages5
JournalAnnals of the New York Academy of Sciences
Volume1284
Issue number1
DOIs
Publication statusPublished - May 2013

Fingerprint

Tumors
Interferons
Neoplasms
Pathogens
Autoimmunity
Grafts
Chemical activation
Immunologic Monitoring
Graft Rejection
Graft vs Host Disease
Multigene Family
Immunotherapy
Allografts
Pathway
Rejection
Genes
Tissue
Growth
Infection

Keywords

  • Autoimmunity
  • Cancer immunotherapy
  • Melanoma
  • Rejection

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Common pathways to tumor rejection. / Wang, Ena; Bedognetti, Davide; Tomei, Sara; Marincola, Francesco M.

In: Annals of the New York Academy of Sciences, Vol. 1284, No. 1, 05.2013, p. 75-79.

Research output: Contribution to journalArticle

@article{4e9c2f0fcb6447b59e4e7c5fc5e6e875,
title = "Common pathways to tumor rejection",
abstract = "The control of tumor growth by the host's immunosurveillance is centered on the activation of interferon (IFN) pathways. In particular, direct study of tumors by various groups has uncovered an IFN-γ-related signature whose presence is consistently associated with better prognosis, predisposition to respond to immunotherapy, and, in its extreme manifestation, the acute phases of tumor rejection. Together, and related to the IFN-γ-associated signature, a cluster of genes are coordinately expressed that we refer to as the immunologic constant of rejection (ICR). Activation of ICR components is observed in all forms of immune-mediated, tissue-specific destruction, including autoimmunity, allograft rejection, graft-versus-host disease, and killing of affected cells during the acute phases of infection that leads to clearance of pathogens. Thus, tumor rejection is a facet of a general and conserved mechanism that favors (tumor rejection, clearance of pathogen) or encumbers (graft rejection, autoimmunity) the organism. Here, we summarize progress in the understanding of its genesis, outline the difficulties, and propose a strategy for understanding the causes of tumor rejection.",
keywords = "Autoimmunity, Cancer immunotherapy, Melanoma, Rejection",
author = "Ena Wang and Davide Bedognetti and Sara Tomei and Marincola, {Francesco M.}",
year = "2013",
month = "5",
doi = "10.1111/nyas.12063",
language = "English",
volume = "1284",
pages = "75--79",
journal = "Annals of The Lyceum of Natural History of New York",
issn = "0890-6564",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Common pathways to tumor rejection

AU - Wang, Ena

AU - Bedognetti, Davide

AU - Tomei, Sara

AU - Marincola, Francesco M.

PY - 2013/5

Y1 - 2013/5

N2 - The control of tumor growth by the host's immunosurveillance is centered on the activation of interferon (IFN) pathways. In particular, direct study of tumors by various groups has uncovered an IFN-γ-related signature whose presence is consistently associated with better prognosis, predisposition to respond to immunotherapy, and, in its extreme manifestation, the acute phases of tumor rejection. Together, and related to the IFN-γ-associated signature, a cluster of genes are coordinately expressed that we refer to as the immunologic constant of rejection (ICR). Activation of ICR components is observed in all forms of immune-mediated, tissue-specific destruction, including autoimmunity, allograft rejection, graft-versus-host disease, and killing of affected cells during the acute phases of infection that leads to clearance of pathogens. Thus, tumor rejection is a facet of a general and conserved mechanism that favors (tumor rejection, clearance of pathogen) or encumbers (graft rejection, autoimmunity) the organism. Here, we summarize progress in the understanding of its genesis, outline the difficulties, and propose a strategy for understanding the causes of tumor rejection.

AB - The control of tumor growth by the host's immunosurveillance is centered on the activation of interferon (IFN) pathways. In particular, direct study of tumors by various groups has uncovered an IFN-γ-related signature whose presence is consistently associated with better prognosis, predisposition to respond to immunotherapy, and, in its extreme manifestation, the acute phases of tumor rejection. Together, and related to the IFN-γ-associated signature, a cluster of genes are coordinately expressed that we refer to as the immunologic constant of rejection (ICR). Activation of ICR components is observed in all forms of immune-mediated, tissue-specific destruction, including autoimmunity, allograft rejection, graft-versus-host disease, and killing of affected cells during the acute phases of infection that leads to clearance of pathogens. Thus, tumor rejection is a facet of a general and conserved mechanism that favors (tumor rejection, clearance of pathogen) or encumbers (graft rejection, autoimmunity) the organism. Here, we summarize progress in the understanding of its genesis, outline the difficulties, and propose a strategy for understanding the causes of tumor rejection.

KW - Autoimmunity

KW - Cancer immunotherapy

KW - Melanoma

KW - Rejection

UR - http://www.scopus.com/inward/record.url?scp=84877346511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877346511&partnerID=8YFLogxK

U2 - 10.1111/nyas.12063

DO - 10.1111/nyas.12063

M3 - Article

VL - 1284

SP - 75

EP - 79

JO - Annals of The Lyceum of Natural History of New York

JF - Annals of The Lyceum of Natural History of New York

SN - 0890-6564

IS - 1

ER -